Lung CT Screening Reporting and Data System
Lung-RADS is the ACR's standardized system for reporting and managing findings on low-dose CT scans performed to screen high-risk people for lung cancer. It sorts each screening exam into a category that signals how concerning the findings are and points to a recommended next step, from routine annual screening to short-interval follow-up to further workup. By standardizing language and follow-up across repeated yearly rounds, it aims to keep false positives low while reliably flagging suspicious nodules. It is the structured reporting system used in practice across U.S. lung-screening programs covered by Medicare.
Added handling for findings not covered before — atypical pulmonary cysts, smooth juxtapleural nodules, and airway nodules — and reworked how suspected infection/inflammation is routed (toward an 'incomplete / short-interval' path rather than an immediate suspicious category). It also clarified how nodule growth is defined.
Refined size criteria — notably raising thresholds so small ground-glass and perifissural nodules no longer triggered escalated follow-up — standardized measurement (mean diameter), and added a short-interval option for new large nodules likely to be infectious/inflammatory.
The original system that first standardized screening-CT reporting and follow-up; it did not yet specifically address infectious/inflammatory findings.
Lung-RADS sorts each screening low-dose CT into a numbered category from 0 to 4, with the 4s subdivided (4A, 4B, and 4X), and adds an optional 'S' modifier for significant incidental findings unrelated to lung cancer. The category reflects the most concerning finding on the exam and is driven mainly by nodule type (solid, part-solid, or ground-glass), size, and whether it is new or growing. Each category carries a recommended management path. Take the exact size thresholds, growth definitions, and follow-up intervals from the official ACR source rather than inferring them.
These are our plain-language summaries. For the exact criteria, thresholds, and management rules, see the official source.
Lung MRI with AI-compressed sensing in single breath-hold achieved 98.1% sensitivity (95% CI 90.2-99.7) for solid nodules ≥4 mm vs PCD-CT, with excellent size agreement (CCC 0.985). Missed calcified nodules <4 mm. Prospective single-center study.
Higher systemic immune-inflammatory index (SII) was associated with malignancy in Lung-RADS 4 lung nodules on LDCT: adjusted difference +272 (95%CI 75-470, P=0.007) and OR 3.74 for SII >561.
The cleanest contrast is Lung-RADS versus the Fleischner Society guidelines: Lung-RADS governs organized screening of asymptomatic high-risk people on repeated annual low-dose CT, while Fleischner addresses nodules found incidentally on a CT done for some other reason. They are not interchangeable — Fleischner explicitly defers to Lung-RADS for screen-detected nodules — and applying the wrong one can change follow-up timing and biopsy thresholds for the same nodule. Lung-RADS is also distinct from non-U.S. screening frameworks such as the British Thoracic Society guidance. (Note: U.S. Medicare coverage requires a standardized classification/reporting system without naming Lung-RADS exclusively, but Lung-RADS is the de facto standard.)
The case for low-dose CT screening that Lung-RADS operationalizes rests on two landmark randomized trials: the U.S. National Lung Screening Trial showed roughly a 20% relative reduction in lung-cancer mortality versus chest radiography, and Europe's NELSON trial confirmed a comparable benefit with a volume-based approach and low workup rates. Retrospective application of Lung-RADS to NLST data sharply lowered false-positive rates versus the trial's original criteria, at the cost of modestly lower sensitivity. Reliability is generally good for solid nodules but degrades for subsolid ones, where a small solid component reduces agreement. A practical caveat is that Medicare eligibility is slightly narrower than the 2021 USPSTF recommendation (age 50–80, at least 20 pack-years).
RadPigeon is an independent radiology news digest and is not affiliated with or endorsed by American College of Radiology (ACR). “Lung-RADS” is a trademark of its owner and is named here only to refer to the system. Always consult the official source for the exact, current criteria.